This is an invention of a process and combination of ingredients in producing an novel herbal energy tea that is ready to drink. This tea is composed of elderberry dandelion, rose petals and rose hips, Mexican honeysuckle, yohimbe and agave nectar. This tea is yohimbe, elderberry, and Mexican honeysuckle based. The tea is not tea leaf based. There are currently no other products on the market in the United States that are similar to this product. It is the first, a novelty. The process of making an organic drinkable herbal energy tea product also includes the distinct process of using distilled water and or spring water. This also makes the process distinct and novel, because it is the first process that does not use municipal filtered water (which may contain cross contaminants) in the production of energy tea drinks. In addition yohimbe (tree bark) is the stimulant of choice as opposed to caffeine and other market stimulants. The sum of ingredients included in the process and production work synergistically to support vital organ function.

Brewing the ingredients require a short process of initial high heat of up to 212 degrees Fahrenheit, then simmering for 1 and a half hours at a temperature of 75 degrees. After simmering, the tea goes through a double micro filtration process extracting solid waste by-products. Thereafter, sweeteners and extracts are mixed and added to the warm cooling brew arriving the product to final settle and cool ready for storage or distribution.

The present invention relates to the use of a cannabidiol (CBD) preparation in the treatment of Fragile X syndrome (FXS). In particular the CBD preparation is characterized by chemical components and/or functional properties that distinguish them from prior CBD compositions. Preferably the CBD used is in the form of a botanically derived purified CBD which comprises greater than or equal to 98% (w/w) CBD and less than or equal to 2% (w/w) of other cannabinoids. The other cannabinoids present are THC at a concentration of less than or equal to 0.1% (w/w); CBD-C1 at a concentration of less than or equal to 0.15% (w/w); CBDV at a concentration of less than or equal to 0.8% (w/w); and CBD-C4 at a concentration of less than or equal to 0.4% (w/w). The botanically derived purified CBD preferably also comprises a mixture of both trans-THC and cis-THC. Alternatively, a synthetically produced CBD is used.

A method for production of red ginseng hydrolysis concentrate according to an embodiment of the present disclosure includes carrying out an enzyme reaction of red ginseng concentrate by adding an enzyme solution followed by addition of alcohol to prepare a mixture solution of red ginseng and alcohol, and centrifuging the prepared mixture solution of red ginseng and alcohol followed by concentration under reduced pressure of a supernatant separated by the centrifuge, and a red ginseng hydrolysis concentrate produced by the aforementioned process.

A method for performing a multi-phase extraction of plant biomass to obtain active substances is provided. The method uses a novel freeze-dry extraction technique to obtain a volatile terpene fraction from frozen plant material. In particular, the method disclosed provides terpene extracts with compositions that strongly resemble that of the parent plant material.

The invention relates to a Cleome droserifolia extract for topical application to the skin and/or mucous membranes. The invention also relates to the use of such an extract as well as to a process for obtaining it and to the compositions containing same.

An extract of an herbal composition comprising at least two different dried plants useful as antimicrobial and/or antibiofilm agent in the treatment or prevention of microbial infections caused by bacteria, such as for example Escherichia, Klebsiella, Listeria, Pseudomonas, Salmonella, Streptococcus or Staphylococcus, or by fungi, such as for example is herein described. It has been found that in such extract, the active ingredients exert their biological effects in a synergistic manner. The extract may constitute the active ingredient of a food supplement, a nutraceutical, pharmaceutical or cosmetic composition or a functional food or a food additive. A process for preparing said extract is also described here.

A method of preparing a liquid dietary supplement includes extracting kavalactones from a Kava plant. The method also includes heating water to a defined temperature and providing the kavalactones and the heated water to the homogenizer. Further, the method includes homogenizing the mixture and generating a slurry of Kava and water. Further still, the method includes agitating the slurry and the water with a mixer.

A method for preparing a liquid dietary supplement includes extracting kavalactones from a Kava plant, heating water to approximately 160° Fahrenheit, and mixing kavalactones with sugar in a 1:2 ration creating a Kava/sugar mixture. The method also includes pouring Kava/sugar and heated water into a mixer, mixing, for approximately twenty (20) minutes, and pumping mixed Kava/sugar through a filter bag generating a slurry. Further the method includes adding the slurry to water heated to 55° Fahrenheit and agitating the slurry and the water heated to 55° with a mixer.

A process for extracting a target compound from a biomass includes: extracting a compound from a biomass charge using supercritical or subcritical CO.sub.2 as a solvent, at a first pressure and a first temperature, to yield a compound-laden solvent stream, the compound-laden solvent stream including the solvent, a solubilized target compound, and a solubilized byproduct compound; changing the temperature while maintaining the first pressure of the compound-laden solvent stream to desolubilize the byproduct compound from the compound-laden solvent stream to yield a resultant stream containing the solvent, the solubilized target compound, and a desolubilized byproduct compound; passing the resultant stream through a filter medium to separate the desolubilized byproduct compound from the solubilized target compound; and collecting the solubilized target compound.

The present invention provides improved solvents, methods, and systems for isolating purified cannabinoids from various sources. It has been found that C.sub.9 to C.sub.11 non-aromatic hydrocarbon solvents, and especially n-decane, work surprisingly well for crystallization of cannabinoids such as cannabidiol. Some variations provide a method of isolating cannabinoids from a cannabinoid-containing solution, comprising contacting the solution with a C.sub.9-C.sub.11 non-aromatic hydrocarbon solvent (e.g., n-decane) at a first temperature, to generate a mixture; cooling the mixture to precipitate cannabinoids; and isolating the precipitated cannabinoids. Other variations provide a method of isolating cannabinoids from a cannabinoid-containing solution, comprising contacting the solution with a C.sub.9-C.sub.11 non-aromatic hydrocarbon solvent (e.g., n-decane) at a first temperature below the solvent boiling point, to generate a mixture; subjecting the mixture to a second temperature that causes vaporization of the solvent, to precipitate at least some of the cannabinoids; and isolating the precipitated cannabinoids.